https://orcid.org/0009-0003-8484-3661
References
- Stern J, Pier J, Litonjua AA. Asthma epidemiology and risk factors. Semin Immunopathol. 2020;42(1):5–15. doi:10.1007/s00281-020-00785-1.
- Jandus P, Duc M, Fay BC. Diagnosis and management of severe asthma in Switzerland: analysis of survey results conducted with specialists and general practitioners. Respiration. 2021;100(6):476–487. doi:10.1159/000514628.
- Global Initiative for Asthma. Global strategy for asthma management and prevention; 2022. Available from: www.ginasthama.org
- Rinaldo RF, Imeri G, Mondoni M, Parazzini EM, Vigo B, Masseroni A, Centanni S, Di Marco F. Does the severity of asthma affect exercise capacity and daily physical activity? J Asthma. 2023;60(8):1622–1631. doi:10.1080/02770903.2023.2169932.
- Frøssing L, Silberbrandt A, Von Bülow A, Backer V, Porsbjerg C. The prevalence of subtypes of type 2 inflammation in an unselected population of patients with severe asthma. J Allergy Clin Immunol Pract. 2021;9(3):1267–1275. doi:10.1016/j.jaip.2020.09.051.
- Pouliquen IJ, Kornmann O, Barton SV, Price JA, Ortega HG. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. Int J Clin Pharmacol Ther. 2015;53(12):1015–1027. doi:10.5414/CP202446.
- Korn S, Cook B, Simpson LJ, Llanos JP, Ambrose CS. Efficacy of biologics in severe, uncontrolled asthma stratified by blood eosinophil count: a systematic review. Adv Ther. 2023;40(7):2944–2964. doi:10.1007/s12325-023-02514-0.
- Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, Barros M, Buhl R, Howarth P, Albers FC, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143(5):1742–1751.e7. doi:10.1016/j.jaci.2018.09.033.
- Baccelli A, Koćwin M, Parazzini EM, Rinaldo RF, Centanni S. Long-term outcomes of combination biologic therapy in uncontrolled severe asthma: a case study. J Asthma. 2023;60(5):1050–1053. doi:10.1080/02770903.2022.2109162.
- Bölke G, Tong X, Zuberbier T, Bousquet J, Bergmann KC. Extension of mepolizumab injection intervals as potential of saving costs in well controlled patients with severe eosinophilic asthma. World Allergy Organ J. 2022;15(10):100703. doi:10.1016/j.waojou.2022.100703.
- Bernstein D, Pavord ID, Chapman KR, Follows R, Bentley JH, Pouliquen I, Bradford E. Usability of mepolizumab single-use prefilled autoinjector for patient self-administration. J Asthma. 2020;57(9):987–998. doi:10.1080/02770903.2019.1630641.
- Moore WC, Kornmann O, Humbert M, Poirier C, Bel EH, Kaneko N, Smith SG, Martin N, Gilson MJ, Price RG, et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). Eur Respir J. 2021;59(1):2100396. doi:10.1183/13993003.00396-2021.